After Eli Lilly (LLY) reported topline data from the Phase 3b SURMOUNT-5 trial, which ran a head-to-head comparison between Zepbound, or tirzepatide, and Novo Nordisk’s (NVO) Wegovy, or semaglutide, in overweight and obese adults, BTIG notes that the data affirms the superior profile of tirzepatide, which showed 20.2% weight loss at 72 weeks vs. 16.1% for semaglutide. The firm believes the greater weight loss seen at three months with Viking Therapeutics’ (VKTX) VK2735 will further deepen with time and sees the potential for ‘2735 to differentiate from tirzepatide not only on absolute weight loss but also on dosing frequency and tolerability, supporting a potential best-in-class profile. BTIG reiterates a Buy rating and $125 price target on Viking shares.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Viking Therapeutics initiated with an Overweight at Piper Sandler
- Viking’s VK2735 outpacing Amgen’s MariTide, says H.C. Wainwright
- Positive Phase 2 Trial Results Drive Viking Therapeutics (VKTX) Stock Upwards
- Viking Therapeutics initiated with a Buy at B. Riley
- Viking Therapeutics reports results from Phase 2b clinical trial of VK2809